Roxadustat for Patients with Posttransplant Anemia: A Narrative Review

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review

Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Ro...

Full description

Bibliographic Details
Main Authors: Xiaoxiao Tang, Fei Liu, Qiuyu Li, Jianhua Mao
Format: Article
Language:English
Published: Karger Publishers 2023-11-01
Series:Kidney Diseases
Subjects:
roxadustat
hypoxia-inducible factor
renal transplantation
anemia
Online Access:https://beta.karger.com/Article/FullText/535071

Similar Items

Similar Items